Newron Provides Update Following Type A Meeting With the FDA

Newron (NWRN) issued an update following a Type A meeting with the FDA regarding its ENIGMA TRS 2 study in the US. The announcement, as provided, contains no quantified FDA decision or trial outcome details, implying limited immediate incremental impact for investors.

Analysis

Newron (NWRN) issued an update following a Type A meeting with the FDA regarding its ENIGMA TRS 2 study in the US. The announcement, as provided, contains no quantified FDA decision or trial outcome details, implying limited immediate incremental impact for investors.